cabozantinib

Known as: 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide 
An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor… (More)
Is this relevant?
2015
2015
PURPOSE ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a… (More)
Is this relevant?
2014
2014
BACKGROUND Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial… (More)
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with… (More)
Is this relevant?